Please login to the form below
PD-1
This page shows the latest PD-1 news and features for those working in and with pharma, biotech and healthcare.
Roche pulls EU Tecentriq/Avastin filing in kidney cancer
Bristol-Myers Squibb’s combination of PD-1 inhibitor Opdivo (nivolumab) and CTLA4 inhibitor Yervoy (ipilimumab) had been turned down by the CHMP earlier this year on the grounds that adding ... It’s good news for BMS, which has been trying to defend
Latest news
-
AZ’s MYSTIC survival data is in – and it’s a bust
There’s no doubt that overall the study is a big disappointment, and will allow Merck &Co’s rival PD-1 inhibitor Keytruda (pembrolizumab) to maintain its fierce grip on the ... We are encouraged to see that Imfinzi monotherapy activity is in-line
-
AZ drug matched to cancer mutation passes phase 2 test
AKT E17K is present in about 1% of all tumours and is particularly common in prostate cancer. ... The first approvals for type-agnostic therapies have already been granted, with Merck/MSD’s Keytruda (pembrolizumab( and Bristol-Myers Squibb’s Opdivo
-
Soon-Shiong presents first data on cancer memory vaccine at SITC
Its ‘memory cancer vaccine’consists of a cocktail of off-the-shelf NK cells delivered alongside low-dose chemotherapy, cytokines, yeast- and adenovirus-delivered tumour antigens and PD-1/PD-L1
-
BMS CEO tackles investor ‘frustrations’ on immuno-oncology
BMS was the pathfinder for the checkpoint inhibitor market with its CTLA4 inhibitor Yervoy (ipilimumab) and PD-1 blocker Opdivo (nivolumab), However, it has since lost ground to rival Merck ... MSD, whose PD-1 drug Keytruda (pembrolizumab) outsold Opdivo
-
AZ swells immuno-oncology pipeline with Innate deal
Mondher Mahjoubi. There are established ties between the two companies, as monalizumab is already being trialled in combination with AZ’s PD-L1 inhibitor Imfinzi (durvalumab), which stems from an initial ... 1/PD-L1 drugs.
More from news
Approximately 21 fully matching, plus 259 partially matching documents found.
Latest Intelligence
-
Chinese biotech’s global ambitions
The company has a PD-1 cancer immunotherapy, tislelizumab, in development in China, and believes it can compete in the market alongside multinationals MSD (Merck in the US) and BMS and ... PD-1 contender filed in China. The company has just announced
-
Made in China
Multinationals such as AstraZeneca and Pfizer have posted astonishing growth in China this year by catering to the vast needs of the country’s population of 1.39 billion people. ... It has just submitted its PD-1 immunotherapy candidate tislelizumab
-
Cancer immunotherapy: What's on the horizon?
Non-small cell lung cancer (NSCLC) is a prime example of the impact the new PD-(L) 1 drugs can have. ... Among the plethora in the pipeline, Aurigene and BMS are looking at PD-1 inhibitors that can be dosed orally, Novartis, iTeos and Aduro are
-
Deal Watch January 2018
Option, collaboration. 1, 063. Syros Pharmaceuticals/ Incyte. Gene control platform to identify up to seven therapeutic targets with a focus in myeloproliferative neoplasms. ... used to progress the clinical development of the company's immuno-oncology
-
The good, the bad and the ugly
But that doesn’t tell the whole story. Pfizer comfortably remains the world’s largest pharma company (by global Rx sales), with an estimated 12.1% growth in 2017, lifting its ... Companies are looking to pair their PD-1/PD-L1 checkpoint inhibitors
More from intelligence
Approximately 0 fully matching, plus 27 partially matching documents found.
Latest appointments
-
Crescendo Biologics appoints Dr Kevin Johnson as chairman
Crescendo's discovery programmes are focused on the development of innovative medicines for the treatment of cancer, including its proprietary Humabody Drug Conjugates (HDCs) and checkpoint modulators such as ... 1 Humabodies.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
A stumble, but not a fall – what’s next for Opdivo?
Opdivo works via PD-1 immune checkpoint inhibition, which involves reactivating T-cells (a subtype of white blood cell) and decreasing tumor growth.
-
Immuno-oncology: The market opportunity for PD-1/PD-L1s
Immuno-oncology: The market opportunity for PD-1/PD-L1s. Immuno-oncology is the new frontier in cancer treatment. ... Of these therapies, immune checkpoint inhibitors are showing particular promise.Our latest infographic is a snapshot of the PD-1/PD-L1
-
Immuno-oncology: The market opportunity for PD-1/PD-L1s
Immuno-oncology: The market opportunity for PD-1/PD-L1s. Immuno-oncology is the new frontier in cancer treatment. ... Of these therapies, immune checkpoint inhibitors are showing particular promise.Our latest infographic is a snapshot of the PD-1/PD-L1
-
Research Partnership
Published in PBIRG Perspective, May 2016, vol. 18 No.1, By Julie Denny, Marketing Director. ... Published in PBIRG Perspective, May 2016, vol. 18 No.1, By Julie Denny, Marketing Director.
More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.
Featured jobs
- Programme Director, Healthcare PR, Highly competitive package
-
Highly Competitive package
- Director, Market Access / HEOR - North-West
-
Negotiable
- Senior Medical Writer (Remote Working)
-
Competitive Salary Offered
-
Medical Writers
-
Competitive Salary and Benefits
-
Associate Medical Director
-
Highly Competitive
-
Account Manager / Account Director
-
Competative
- Events Manager – Med Comms – Surrey
-
Salary TBC
-
Associate Director
-
£75, 000-90, 000
-
Account Director
-
£48, 000 - £60, 000
- Account Manager, Healthcare Public Affairs
-
£32, 000 – £40, 000 benefits
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
-
Senior Medical Writer
-
Great salary and benefits
-
New Business Director - PR
-
Competitive Salary and benefits
-
SENIOR MEDICAL WRITER IN ONCOLOGY
-
Up to £60, 000.00 pension bonus
- Senior Systematic Review Analyst - Oxford
-
Negotiable
Subscribe to our email news alerts
- Animal Health Diagnostics Market Forecast Showing 9.53% CAGR to 2022
- Iron Drugs Market Set to Register 9.27% CAGR to 2022
- Medical Device Manufacturing Outsourcing Market to Soar at 11.92% CAGR to 2022
- Plaque Modification Devices Market Forecast Showing 8.19% CAGR to 2022
- Radiotherapy Market | Global Industry Analysis, Segments, Top Key Players, Drivers and Trends to 2023
- Migraine Therapeutics Market Forecast Showing 5.38% CAGR to 2022
PMHub
VCCP Health
We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...
Latest intelligence
- OUTiCO win Best in UK Pharmaceutical Outsourcing award
- The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
- Artificial Intelligence in Healthcare
- Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
- World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
- Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
Quick links
Infographics
